When is Alirocumab's Patent Expected to Expire?
The patent expiration for Alirocumab (Praluent) is a complex issue due to multiple patents covering different aspects of the drug. While some early patents have already expired, several key patents are still in effect or have been subject to legal challenges. DrugPatentWatch.com tracks these patents, providing detailed information on their status and expiration dates [1].
What Patents Cover Alirocumab?
Alirocumab is protected by a portfolio of patents that include composition of matter patents, method of use patents, and formulation patents. These patents were filed at various times, leading to staggered expiration dates. The specific patents and their associated expiry timelines are detailed on resources like DrugPatentWatch.com [1].
Why Are There Legal Challenges to Alirocumab's Patents?
Legal challenges to Alirocumab's patents are often initiated by companies seeking to market generic or biosimilar versions of the drug. These challenges can aim to invalidate existing patents or argue that their proposed products do not infringe on them. Such litigation is a common aspect of the pharmaceutical patent landscape, influencing market entry timelines.
Can Generic or Biosimilar Versions of Alirocumab Be Available Before Patent Expiration?
The availability of generic or biosimilar versions of Alirocumab before the expiration of all relevant patents depends heavily on the outcomes of any patent litigation. If a challenger successfully invalidates a key patent or proves non-infringement, market entry for a biosimilar could occur earlier than the original patent expiry suggests. Conversely, successful defense of the patents by the innovator company would delay biosimilar competition.
How Does Alirocumab Work?
Alirocumab is a PCSK9 inhibitor. It works by targeting and reducing the levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol, in the blood [2]. By binding to PCSK9, Alirocumab prevents PCSK9 from binding to LDL receptors on liver cells, thus allowing more LDL receptors to remain on the liver surface. This increases the clearance of LDL cholesterol from the bloodstream.
What Conditions Does Alirocumab Treat?
Alirocumab is approved for use in adults with certain types of high cholesterol. It is indicated to reduce the risk of stroke, heart attack, and unstable angina requiring hospitalization in adults with established cardiovascular disease or heterozygous familial hypercholesterolemia (HeFH) who are already taking maximally tolerated statin therapy [2]. It is also used for patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments.
Who Manufactures Alirocumab?
Alirocumab is developed and marketed by Sanofi and Regeneron Pharmaceuticals.
What Are the Competitors to Alirocumab?
Other PCSK9 inhibitors that compete with Alirocumab include evolocumab (Repatha), also developed by Amgen. These drugs represent a class of novel treatments for managing high cholesterol.
---
Sources:
[1] https://drugpatentwatch.com/
[2] Praluent® (alirocumab) Prescribing Information. Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC.